← Product Code [MXK](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/MXK) · K031788 # PATHFINDER (K031788) _Massie Research Laboratories, Inc. · MXK · Sep 2, 2004 · Ophthalmic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/MXK/K031788 ## Device Facts - **Applicant:** Massie Research Laboratories, Inc. - **Product Code:** [MXK](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/MXK.md) - **Decision Date:** Sep 2, 2004 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 886.1850 - **Device Class:** Class 2 - **Review Panel:** Ophthalmic ## Indications for Use For general ophthalmic imaging, visualization, and fluorescein angiography including anterior and posterior segments of the eye. ## Device Story Anterior Segment Analysis Device (Pathfinder) provides ophthalmic imaging and visualization; supports fluorescein angiography. Device captures images of anterior and posterior eye segments. Used in clinical settings by eye care professionals to assist in diagnostic visualization. Output consists of ocular images for clinician review to support clinical decision-making regarding eye health and pathology. ## Clinical Evidence No clinical data provided; substantial equivalence determination based on device description and intended use. ## Technological Characteristics Ophthalmic imaging system designed for anterior and posterior segment visualization. Supports fluorescein angiography. Technical specifications and materials not detailed in the provided documentation. ## Regulatory Identification An AC-powered slitlamp biomicroscope is an AC-powered device that is a microscope intended for use in eye examination that projects into a patient's eye through a control diaphragm a thin, intense beam of light. ## Special Controls *Classification.* Class II (special controls). The device, when it is intended only for the visual examination of the anterior segment of the eye, is classified as Group 1 per FDA-recognized consensus standard ANSI Z80.36, does not provide any quantitative output, and is not intended for screening or automated diagnostic indications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9. ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three stripes representing human services. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 SEP - 2 2004 Massie Research Laboratories, Inc. c/o N.A. (Bert) Massie, Ph.D. 5775 W. Las Positas Blvd Suite 200 Pleasanton, CA 94588-4084 Re: K031788 Trade/Device Name: Anterior Segment Analysis Device Regulation Number: 21 CFR 886.1850 Regulatory Class: Class II Product Code: MXK Dated: July 31, 2004 Received: August 2, 2004 Dear Mr. Massie: We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your bection of the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the Clerosury to regars actuent date of the Medical Device Amendments, or to commerce price to May 20, 1976, the excordance with the provisions of the Federal Food, Drug, devices that have been recuire approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The You may, therefore, market the device, Books requirements for annual registration, listing of general controls provisions of ractice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your device is classified (800 a0070) als. Existing major regulations affecting your device can thay be subject to suen additions, Title 21, Parts 800 to 898. In addition, FDA may be found in the Oucements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean I loast be devised that i Dr rivetion that your device complies with other requirements of the Act that I DA has made a acterialized administered by other Federal agencies. You must of any I edelin Statutes and regurements, including, but not limited to: registration and listing compry with and 100 recess requirements Part 801); good manufacturing practice requirements as set (21 CFR Part 807), accems (QS) regulation (21 CFR Part 820); and if applicable, the electronic form in the quant) byevelles (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ Page 2- N.A. (Bert) Massie, Ph.D. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Alegi Rosenthal A. Ralph Rosenthal, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ K031788 510(k) Number : Device Name: Pathfinder or other to be determined Indications for use: For general ophthalmic imaging, visualization, and fluorescein angiography including anterior and posterior segments of the eye. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-the-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Sean L Keefe (Division Sign-Off) Division of Ophthalmic Ear, Nose and Throat Devises 510(k) Number_________________________________________________________________________________________________________________________________________________________________ --- **Source:** [https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/MXK/K031788](https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/MXK/K031788) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com